دواعي استعمال روبينيرول 0.25مجم 10 اقراص

Ropinirole 0.25 mg oral tablets, pack of 10, by EPCI (Egypt); non-ergoline dopamine agonist.

• Treatment of Parkinson's disease.الفئة: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).الفئة: AdultsDailyMed (U.S. National Library of Medicine)

• Early Parkinson's disease: nausea, somnolence, dizziness, syncope, asthenic condition, viral infection, leg edema, vomiting, dyspepsia.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Advanced Parkinson's disease: dyskinesia, somnolence, nausea, dizziness, confusion, hallucinations, sweating, headache.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• RLS: nausea, vomiting, somnolence, dizziness, asthenic condition.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or any excipient.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Falling asleep during activities of daily living (including driving) and somnolence, sometimes without warning signs.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Syncope (sometimes with bradycardia) and hypotension/orthostatic hypotension, especially during dose escalation.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Hallucinations/psychotic-like behavior, dyskinesia, and impulse-control/compulsive behaviors (gambling, sexual urges, spending, binge eating).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Withdrawal-emergent hyperpyrexia and confusion and withdrawal symptoms; taper at end of treatment. Augmentation/early-morning rebound in RLS; fibrotic complications; retinal pathology.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• CYP1A2 inhibitors/inducers (e.g. ciprofloxacin; cigarette smoking)CYP1A2 is the major metabolic enzyme; ciprofloxacin increases ropinirole AUC and Cmax, smoking is expected to increase clearance; dose adjustment may be required when such drugs are started or stopped.DailyMed (U.S. National Library of Medicine)
• Estrogens (hormone replacement therapy)Higher estrogen doses reduce ropinirole clearance; starting or stopping HRT may require dose adjustment.DailyMed (U.S. National Library of Medicine)
• Dopamine antagonists (neuroleptics, metoclopramide)May reduce the efficacy of ropinirole.DailyMed (U.S. National Library of Medicine)

• No adequate data on developmental risk in pregnant women; in rats ropinirole caused adverse developmental effects (neurobehavioral impairment at doses similar to the MRHD; teratogenicity and embryolethality at >36 times the MRHD).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; inhibition of lactation is expected because ropinirole inhibits prolactin secretion. Weigh benefits of breastfeeding against maternal need and potential infant effects.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Monitor for signs and symptoms of orthostatic hypotension, especially during dose escalation; ask patients about new or increased impulsive urges.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Thought to act by stimulating dopamine D2 receptors within the caudate-putamen; precise mechanism unknown (US label 12.1).